Clinical Trial Update: 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism [Phase 3]

View source ↗

Summary

Clinical trial update for XYOSTED in adolescent males with hypogonadism, detailing a 52-week Phase 3 study plus a 24-month long-term extension to evaluate safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypogonadism

Drugs mentioned

• XYOSTED (Testosterone enanthate)

Snippet

Sponsor: Halozyme Therapeutics | Conditions: Hypogonadism, Male | Phase 3 | Status: RECRUITING